Brigitte Guérin accepted a tenure-track faculty position at Université de Sherbrooke in 2007. A full professor at the Department of Nuclear Medicine and Radiobiology, she is also head of the Radiochemistry Laboratory at Université de Sherbrooke Hospital’s Molecular Imaging Centre. She holds the Jeanne-and-J.-Louis-Lévesque Chair in Radiobiology at Université de Sherbrooke. Her original research program is based on extensive know-how and expertise in the area of radiochemistry ⎼ a highly specialized niche in organic chemistry. She has forged an international reputation for excellence, consolidating Canadian leadership in the development of new molecular tools and radiopharmaceuticals for the purposes of molecular PET imaging and targeted therapy. Examples of her achievements include the nuclear-waste free, cyclotron-based production of Technetium-99m in response to world shortages of medical radioisotopes, as well as bringing to the clinic new and known radiopharmaceuticals ⎼ such as the [68Ga]-DOTA-TATE for detection and treatment follow-up of neuroendocrine cancers. This tracer is available to cancer patients in Canada through her work. She has published over 79 scientific articles in peer-reviewed journals, has patents pending, has advanced 13 radiotracers from the bench to clinical trial, has given 38 invited lectures at international scientific meetings, and has vulgarized her work on non-reactor produced technetium-99m for public media in both official languages. With the International Atomic Energy Agency, she is implementing her developments through an international collaborative Radiochemistry Visiting Program.